

NASDAQ Bio Pharmaceutical and Wellness Company approved for Dual Listing on Upstream; Jupiter Wellness, Inc NASDAQ: JUPW

Trading to Commence January 10, 2023, Under Upstream Ticker Symbol \$JUPW; all Shareholders to Receive Commemorative NFT

JUPITER, FLORIDA, UNITED STATES, December 13, 2022 / EINPresswire.com/ -- NASDAQ Bio-Pharmaceutical and Wellness Company approved for Dual Listing on Upstream; Rising Revenues and a Comprehensive Corporate Update; NASDAQ: JUPW



Trading to Commence January 10, 2023, Under Upstream Ticker Symbol \$JUPW; all Shareholders to Receive Commemorative NFT

“

Building shareholder value is a goal of ours. We believe a dual listing on Upstream will expand the ways we reach potential supporters and give us access to innovative new ways to introduce JUPW”

Brian John, CEO of JUPW

- Active Research Programs Developing Multiple Health & Wellness Product Lines.
- Growing Revenues from Consumer Products, Contract Research, and Licensing.
- New BOD Member was Appointed who Reported an Insider Purchase of 122,000 Shares.
- Exclusive Licensing Agreement with Rejoy, Inc. to Develop Products for Various Treatments in Women with

Cancer.

□ Notice of Allowance for Patent Titled "Minoxidil Adjuvant Therapies."

□ Clinical Trial Comparison of JW-100 and EUCRISA for the Treatment of Eczema.

□ JUPW Shares Currently Considered Over-Sold & Over-Shorted by Watch Groups.

\$JUPW has received approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Trading begins on Upstream January 10, 2023, at 10:00 am ET under the ticker symbol JUPW.

Global investors can get ready to trade by creating an account on Upstream and completing a simple KYC identity verification.* Details on the Jupiter Wellness listing and how shareholders can deposit shares and trade on Upstream can be found at <https://jupiterwellness.com/investors/shareholder-faq/>. The Upstream market is open 5 days a week 20 hours a day, Monday to Friday: 10:00 am to 06:00 am UTC+4 (1:00 am to 9:00 pm EST).

The dual listing on Upstream is designed to provide Jupiter Wellness the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with a credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in the Company.


SHAREHOLDER LETTER:

BRINGING LIFE-CHANGING INGREDIENTS TO EVERY-DAY PRODUCTS

Jupiter Wellness Inc.
NASDAQ Stock Symbol: JUPW


BRANDS

AWARD-WINNING PRODUCTS



JUPW Products Brands

MINOXIDIL BOOSTER



Product
Topical treatment designed to improve Minoxidil efficacy.

Studies
Clinically shown to increase the enzymes needed for minoxidil to work, sulfotransferase enzymes, by up to 7x over a two-week period.

Sales Channels
Licensed to Taisho, a \$2.6 billion revenue company and Japan's leading seller of minoxidil products. A \$300k up-front payment was received with 3% royalties on net sales. They expect to launch the product commercially in 2023.


Licensed to India-based Cosmofix Technovation Pvt Ltd and Sanpellegrino Cosmetics. A \$50k up-front payment was received with 10% royalties on net sales. The timeframe for their commercial product launch has not been established.

\$JUPW Minoxidil

"I've been using CaniSun sunscreen and I love the product. This is an easy endorsement for someone who's in the sun as much as i am."


ERNIE ELS

READ FULL NEWS



JUPW Ernie Els

JW-100



Product
Topical treatment of atopic dermatitis (eczema).

Studies
JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs.

A Phase 3, double-blind, placebo-controlled multi-center trial is underway to evaluate the superiority of JW-100 to Eucrisa (an FDA-approved topical drug) in mild-to-moderate eczema.

Sales Channels
JW-100 is pre-revenue.

Next Steps
Market analysis and go-to-market plans are being developed with an anticipated product launch in 2023.

\$JUPW Eucrisa

Dear Shareholders of [Jupiter Wellness, Inc. \(NASDAQ: JUPW\)](#)

I would like to take this opportunity to review the significant progress made by your company since the last Letter to Shareholders dated September 15. We have launched or restarted two clinical trials for tinnitus and eczema, both conditions with large patient populations. We have entered the potentially lucrative market of Female Intimacy Wellness and obtained or added to our intellectual property portfolio with the addition of our hair loss therapy. We finally had our topical treatment for psoriasis and vitiligo approved by the "FDA of India" and just announced the market launch in India. And lastly, we announced record revenues for the Nine Months ending September 30 vs. the corresponding period in 2021.

We have compiled a quick summary of recent developments and an overview of our products and their current disposition - whether already on the market and generating revenues, currently in clinical trials, or in development:

□ Jupiter Wellness Corporate Development Highlights

- United States Patent and Trademark Office (USPTO) granted a notice of allowance for patent application No. 16/747,685, titled "Minoxidil Adjuvant Therapies." The patent encompasses the composition and methods for inducing (up-regulating) the expression of sulfotransferases in the hair follicles on the scalp. It has been shown that the induction of the sulfotransferase enzyme in hair follicles increases the sulfonation capacity of minoxidil, thereby increasing the response level to oral and topical minoxidil in the treatment of alopecia.
- Announced the initiation of a triple-blinded clinical study evaluating a possible treatment for tinnitus. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus. During the COVID-19 pandemic, Jupiter Wellness scientists identified a novel pathway for the treatment of COVID-19-induced tinnitus and possibly subjective tinnitus. The discovery led to a patent recently filed by Jupiter Wellness for the use of dopamine receptor modulation for the treatment of tinnitus. The Company launched a study to investigate if dopamine receptor modulation can be used effectively to treat COVID-19-induced tinnitus (<https://clinicaltrials.gov/ct2/show/NCT05507372>). Currently, there is no effective treatment available for patients suffering from tinnitus.
- Company's Photocil product (branded as PhotoFirst in India) has been approved by the CDSCO for sale in India. The Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services, Ministry of Health & Family Welfare, is the National Regulatory Authority (NRA) of India. Photocil is a topical product that filters UV rays from the sun to allow only the therapeutic UV spectrum to penetrate the skin and is used for the treatment of psoriasis and vitiligo. After this market approval, Eris Oaknet Healthcare Pvt Ltd (Eris Oaknet) and Cosmofix Technovation Pvt Ltd (Cosmofix) had market launch meetings for Photocil products for the Indian market in November. The incidence of psoriasis among total skin patients in India

ranged between 0.44 and 2.2%, with overall incidence of 1.02% (hyperlink: <https://ijdv.com/psoriasis-in-india-prevalence-and-pattern/>). The overall prevalence of vitiligo (hyperlink: <https://pubmed.ncbi.nlm.nih.gov/4054593/>) is about 5 per 1,000 individuals. India has a population of 1.412 billion.

- Announced that it has begun the application process to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). The planned dual listing on Upstream is designed to provide Jupiter Wellness the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with a credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in Jupiter Wellness.
- Re-opened patient enrollment in a clinical trial to evaluate the superiority of JW-100, a novel topical cream, in a head-to-head study against EUCRISA, an FDA Approved topical treatment for eczema developed by Pfizer. The initial study was put on hold to solve stability issues which were resolved in the original JW-100 formulation.
- The Company reported \$1.57 million in revenues for the three months that ended September 30, 2022, compared to \$688K for the same period in 2021, a 228% increase. In addition to the revenues booked in the Third Quarter, Jupiter Wellness's wholly-owned subsidiary, SRM Entertainment, received \$3.6 million in guaranteed purchase orders, with revenues realized once orders are shipped. For the Nine Months that ended Sept. 30, revenues were \$5.29 Million vs. \$1.33 Million, representing a 398% increase over the First Nine Months of 2021.
- On October 25, Jupiter Wellness Acquisition Corp., of which Jupiter Wellness is the sponsor and owns a considerable stake, entered into a definitive business combination agreement with Chijet Motor Company, Inc., which is developing next-generation electric vehicles and expanding its manufacturing capabilities. The deal is expected to be consummated in the next three months.
- The Company retired an additional 391,000 shares to treasury from our share buyback program that ended in June.

Product Overview of Jupiter Wellness Products

- ☐ Minoxidil Booster (TM) - Topical treatment designed to improve Minoxidil efficacy (Approved and on the market)
- ☐ Photocil (TM) - Topical treatment for psoriasis and vitiligo (Licensed and on the market)
- ☐ NoStingz (TM) - Topical protection from jellyfish, sea lice, and UVA/UVB rays (Approved and on the market)
- ☐ JW-100 - Topical treatment of eczema (Currently in development)

- JW-300 - Topical treatment of first-degree burns and sun exposure (Currently in development)
- JW-400 - Topical treatment of cold sores (Currently in development)
- JW-500 - Topical treatment for female Intimacy wellness (Currently in development)
- JW-600 - Treatment for COVID-19-induced tinnitus (Clinical trials underway)

As we head into the end of 2022, we look forward to capitalizing on the progress we have made in building a foundation for continued revenue growth, monetizing our clinical trial programs, building profitability, and enhancing shareholder value.

Please accept my thanks and the gratitude of our entire executive team for your continued support of Jupiter Wellness.

Happy Holidays.

Brian John

DISCLAIMER: This article is purely for informational purposes and is not a recommendation in any way for buying or selling stocks

Brian John, CEO
Jupiter Wellness, Inc
+1 561-244-7100

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/606094414>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.